行 家用电器 2025 年 03 月 16 日 业 研 究 行 业 定 期 报 家用电器 电动自行车以旧换新成效显著，1-2 月扫地机数 据靓丽——25W11 周观点 投资要点： 电动自行车以旧换新成效显著，1-2 月扫地机数据靓丽 告 电动自行车以旧换新成效显著。根据中国经济网援引的商务部数 据，截至 3 月 11 日，今年全国电动自行车售旧、换新 166.4 万辆，超 过 2024 年总和（2024 年以旧换新从 9 月开始），相当于 2024 年工作 总量的 120.4%，累计补贴 10.0 亿元，人均约 600 元，拉动新车销售 45.1 亿元，惠及 4.7 万家销售门店。 国补无缝衔接带动扫地机品类延续亮眼表现。根据奥维云网，受 春节错期影响，1-2 月线上销售呈现前高后低趋势，从可比口径来看， 1-2 月扫地机线上销额 19.16 亿元，同比+72%，线上销量 58.75 万台， 同比+58%，均价为 3261 元，同比+9%。 行情数据 本周家电板块涨跌幅+1.7%，其中白电/黑电/小家电/厨电板块涨跌 幅分别+2.2%/-0.6%/+2.3%/+3.1%。原材料价格方面，LME 铜、LME 铝 ...

行 华福证券 食品饮料 2025 年 03 月 16 日 业 研 究 食品饮料 复苏预期持续强化，白酒进入估值修复阶段 投资要点： 行 业 定 期 报 告 【白酒】春节整体基本面或处于底部待反转区间，同时节后白酒企业密集 停止发货，预计停货对价格的支撑在短期内即可显现，后续价格预期积极， 需求端复苏或缓释销售端压力。白酒作为顺周期板块，预期带动估值修复 往往先于基本面，估值具备较强安全边际和配置属性。建议关注可攻可守 的山西汾酒，保价控量、具备降维打击、市占率提升能力的茅台、五粮液 以及受益于婚宴回补的古井贡酒、今世缘、迎驾贡酒。 【啤酒】重点推荐高端化核心标的青岛啤酒、提效改革叠加大单品逻辑的 燕京啤酒。 【软饮料】建议关注：1）功能饮料赛道龙头且逐步探索出第二增长曲线的 东鹏饮料；2）基本面具备积极预期的香飘飘。 【预调酒】百润股份作为预调酒行业龙头企业，公司历史行情通常为大单 品所驱动的 PE 扩张，行情较快，操作上更适合左侧布局，目前公司威士忌 已正式上市，当前公司 25 年 PE 为 37 倍上下，我们认为具备较大赔率。 【乳制品】重点推荐利润导向明显的全国乳企巨头伊利股份，关注其产品 结构优化带来 ...

Investment Rating - The industry rating is "Outperform the Market" indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 months [7][14]. Core Insights - The latest developments in the AI Agent industry have established a framework consisting of a "Base Model (strong coding capability model) + Operating Platform (as a client) + Universal Interface (MCP builds the bridge)" [2]. - Anthropic has entered the Agent field early with strong product capabilities, launching Claude 3.5 on October 23, 2024, which includes Agent functionalities [4]. - Claude 3.7 has demonstrated superior coding capabilities, reportedly able to solve over 70% of real GitHub issues, outperforming competitors [4]. - Cursor, an AI code editor, has integrated multiple top models and is currently ranked first in popularity among AI programming tools [5]. - MCP, released by Anthropic on November 25, 2024, serves as a standardized interface allowing various external services to connect with AI models, significantly enhancing the ecosystem [6]. Summary by Sections Agent Base Model - Claude - Claude is recognized for its strong coding capabilities, leading the Agent domain with superior performance in software engineering benchmarks [3][4]. Agent Operating Platform - Cursor - Cursor has achieved significant market traction by integrating advanced AI models and is currently valued at nearly $10 billion, following a recent funding round [5]. Agent Universal Interface - MCP - MCP has established a vast ecosystem, supporting over 100 applications and more than 15,000 API operations, facilitating connections with various platforms [6]. Investment Recommendations - The report suggests focusing on entry-level Agents such as Tencent (WeChat AI ecosystem) and Xiaomi (mobile AI ecosystem), as well as B-end Agents like Hand Information and Focus Technology [7].

Investment Rating - The report maintains an "Outperform" rating for the industry [7]. Core Insights - The report highlights the potential of gene therapy for retinal diseases, particularly focusing on the single-dose treatment that could replace long-term injections, with a specific emphasis on Kanghong Pharmaceutical [4][5]. - The global market for retinal diseases, primarily age-related macular degeneration (AMD), is approaching $20 billion and continues to grow, indicating significant unmet medical needs [4][32]. - The report identifies key players in the gene therapy space, including REGENXBIO and AbbVie, with their product ABBV-RGX-314 expected to complete critical Phase 3 clinical trials in 2025 [4][46]. Summary by Sections 1. Market Overview - The CITIC Pharmaceutical Index rose by 1.9% during the week of March 10-14, 2025, outperforming the CSI 300 Index by 0.3 percentage points [3]. - The pharmaceutical sector has shown resilience, with innovative drugs performing well and a positive market sentiment driven by policy changes and new healthcare initiatives [5]. 2. Gene Therapy for Retinal Diseases - Gene therapy is seen as an ideal solution for retinal diseases due to the unique characteristics of the eye, such as immune privilege and low treatment dosage requirements [4][26]. - Current treatments for AMD involve frequent injections, which pose challenges in patient compliance and treatment burden [36]. - Kanghong Pharmaceutical is highlighted for its advanced clinical products KH631 and KH658, which are expected to enter clinical trials in 2023 and 2024, respectively [4][26]. 3. Key Players and Products - ABBV-RGX-314, developed by REGENXBIO and AbbVie, is in Phase 3 trials and has shown promising results in reducing treatment burden by 97% for patients previously requiring frequent injections [64]. - 4DMT's product 4D-150 is designed to inhibit multiple VEGF targets and is expected to significantly reduce treatment needs for wAMD patients [77][89]. - Adverum's Ixo-vec is also entering Phase 3 trials, aiming to provide sustained effects through a single injection [99]. 4. Investment Recommendations - The report recommends focusing on innovative drugs and companies with strong growth potential, particularly those involved in gene therapy and AI applications in healthcare [5][6].

Investment Rating - The report maintains an "Outperform" rating for the electric power equipment and new energy sector [5]. Core Insights - The lithium battery sector shows significant growth in production and sales, with a focus on the upcoming April auto show, indicating a potential peak season [2][13]. - The photovoltaic sector is experiencing a price recovery, with ongoing discussions among major companies to promote healthy industry development [25][26]. - The energy storage sector is expanding, with significant installations planned in Gansu and Inner Mongolia, indicating a stable revenue model [34][36]. - The electric power equipment and industrial control sector is seeing new projects and technological advancements, particularly in high-voltage transmission [45][46]. - The hydrogen energy sector is gaining attention with new standards and projects being initiated, highlighting its growth potential [57][58]. Summary by Sections 1. Lithium Battery and Electric Vehicle Sector - In February, domestic battery production and sales saw a year-on-year increase, with lithium iron phosphate vehicles accounting for 81.5% of the total [13][14]. - The upcoming Shanghai Auto Show is expected to focus on innovation and new models, potentially boosting lithium battery demand [15]. - Companies with cost advantages are likely to outperform competitors, including CATL and others [16][19]. 2. Photovoltaic Sector - The photovoltaic industry is witnessing a price increase due to self-regulation and demand from distributed projects [25][26]. - Major companies are adjusting production quotas, which is expected to lead to a sustained price recovery in the industry [26][27]. - Investment opportunities exist in various segments, including silicon materials and inverters, with specific companies recommended for investment [31]. 3. Energy Storage Sector - By the end of 2024, Gansu's new energy storage capacity is projected to exceed 11GWh, with Inner Mongolia planning significant installations by 2025 [34][36]. - The revenue model for energy storage includes participation in the electricity spot market and auxiliary services [35]. - Investment recommendations focus on quality storage integrators and companies benefiting from the growth in energy storage demand [39]. 4. Electric Power Equipment and Industrial Control Sector - The commencement of the Gansu-Zhejiang high-voltage transmission project is expected to enhance clean energy transmission capabilities [45]. - The sector is also seeing advancements in AI and robotics, with new products being launched [47][51]. - Investment opportunities are highlighted in companies involved in digital grid solutions and automation technologies [52][54]. 5. Hydrogen Energy Sector - The National Energy Administration has outlined key focus areas for hydrogen energy standards by 2025, indicating a strategic direction for the industry [57]. - New projects in hydrogen production and storage are being initiated, with significant investments planned [58][59]. - Companies involved in hydrogen production and fuel cell technologies are recommended for investment [59].

Tabl e_First|Tabl e_Summary 华福证券 电力设备及新能源行业周报 产业周跟踪：光伏产业链价格持续修复，聚焦本 周 GTC 大会 投资要点： ➢ 锂电板块核心观点：锂电2月产销同比高增，4月车展将近酝酿旺季行 情。1）2月国内电池产销同比高增，铁锂装车占比81.5%；2）4月车展聚 焦创新，国内外车企积极推进新车型。 ➢ 光伏板块核心观点：组件价格持续上涨，25H1主材配额调整落地。3 月10-12日光伏硅料-组件环节主要企业在北京再度召开会议，对自律生 产，促进行业健康发展进行讨论。我们认为，随着去年10月以来行业自律 等的实施，当前产业链价格持续修复，同时受430/531节点国内分布式等 项目抢装影响，产业链价格有望进入趋势上涨窗口期。4-5月硅片、电池 等排产增加或将对上游产生一定拉动作用，硅料市场或将在下游需求拉动 下出现一定好转。 ➢ 储能板块核心观点：24年底甘肃新型储能累计装机超11GWh，内蒙古 25年新型储能专项行动累计装机容量约49GWh。1）24年底甘肃新型储能累 计装机4.42GW/11.41GWh，电力现货市场+辅助服务市场+容量租赁为主要 盈利模式；2）内蒙 ...

行 业 3 月 14 日，理想汽车公布 2024 年第四季度及全年财报。2024 年 第四季度，理想汽车共交付 158696 辆，同比增长 20.4%，收入为 443 亿元，同比增长 6.1%，净利润为 35 亿元，同比减少 38.6%。车辆毛利 率下滑是理想汽车净利减少的主要因素之一。2024 年第四季度理想汽 车单车毛利率由 2023 年同期的 22.7%下降至 19.8%。 未来理想汽车将在纯电动汽车和智能驾驶技术方面加大投入。理 想首款纯电 SUV 车型 i8 将于 7 月发布，i6 的发布时间则为今年下半 年。智驾方面，公司正在研发下一代 VLA(视觉-语言-行动)智驾大模型， 并计划与 i8 同时发布。L 系列和 MEGA 也会在今年推出智驾焕新版。 展望 2025 年第一季度，理想汽车预计，车辆交付量为 8.8 万至 9.3 万辆，同比增长 9.5%至 15.7%；收入总额为 234 亿元至 247 亿元，同 比减少 8.7%至 3.5%。 华福证券 本周行情 2025 年 3 月 10 日-3 月 14 日，汽车板块 0.8%，沪深 300 指数 1.6%， 汽车板块跑输沪深 300 指数 0 ...

行 业 研 究 传媒 2025 年 03 月 16 日 海外 Agent 框架：Claude+Cursor+MCP 投资要点： AI Agent 行业的最新发展已形成"基座模型（强代码能力模型）+操 作平台（作为客户端）+万能接口（MCP 搭建桥梁）"的框架逻辑。 一、Agent 基座模型-Claude：代码能力强，在 Agent 领域具优势 行 业 动 Agent 领域，Anthropic 入局早，产品能力强。24 年 10 月 23 日， Anthropic 率先推出包含 Agent 功能 computer use 的 Claude 3.5 sonnet； 11 月公司推出 MCP 开放协议。 态 跟 踪 Claude 代码能力已经领先于众多顶级模型：据 AI 智企报道，在 Web 开发能力方面，最新的 Claude 3.7 理论上能够解决超过 70%的真 实 GitHub 问题，超过其他竞品；在软件工程基准中，OpenAI o3 mini high 和 DeepSeek 均远低于 Claude 3.7。 二、Agent 操作平台-Crusor：深度融合 AI Cursor 深度融合 AI，在 IDE 赛 ...

投资要点： 行 业 定 期 报 告 【白酒】春节整体基本面或处于底部待反转区间，同时节后白酒企业密集 停止发货，预计停货对价格的支撑在短期内即可显现，后续价格预期积极， 需求端复苏或缓释销售端压力。白酒作为顺周期板块，预期带动估值修复 往往先于基本面，估值具备较强安全边际和配置属性。建议关注可攻可守 的山西汾酒，保价控量、具备降维打击、市占率提升能力的茅台、五粮液 以及受益于婚宴回补的古井贡酒、今世缘、迎驾贡酒。 行 华福证券 食品饮料 2025 年 03 月 16 日 业 研 究 食品饮料 复苏预期持续强化，白酒进入估值修复阶段 【啤酒】重点推荐高端化核心标的青岛啤酒、提效改革叠加大单品逻辑的 燕京啤酒。 【软饮料】建议关注：1）功能饮料赛道龙头且逐步探索出第二增长曲线的 东鹏饮料；2）基本面具备积极预期的香飘飘。 【预调酒】百润股份作为预调酒行业龙头企业，公司历史行情通常为大单 品所驱动的 PE 扩张，行情较快，操作上更适合左侧布局，目前公司威士忌 已正式上市，当前公司 25 年 PE 为 37 倍上下，我们认为具备较大赔率。 【乳制品】重点推荐利润导向明显的全国乳企巨头伊利股份，关注其产品 结构优化带来 ...

行 华福证券 医药生物 2025 年 03 月 16 日 业 研 究 医药生物 眼底病基因治疗：单次给药替代长期注射，国内 关注康弘药业 投资要点： 行 业 定 期 报 告 行情回顾：本周（2025 年 3 月 10 日- 2025 年 3 月 14 日）中信医药指 数上涨 1.9%，跑赢沪深 300 指数 0.3 pct，在中信一级行业分类中排名第 14 位；2025 年初至今中信医药生物板块指数上涨 4.0%，跑赢沪深 300 指数 2.1 pct，在中信行业分类中排名第 16 位。本周涨幅前五的个股为：金城医 药（+42.43%）、塞力医疗（+34.47%）、老百姓（+22.47%）、达嘉维康 （+21.14%）、康芝药业（+20.50%）。 眼底病基因治疗技术：单次给药替代长期注射，国内关注康弘药业：由于 眼部具有血视网膜屏障、体积较小因而需要的治疗剂量相对较低、且具有免疫 豁免特性，因而是基因治疗应用的理想组织，目前全球在研基因治疗项目超过 1000 个，涵盖 30 种眼部疾病。目前眼科市场中以眼底新生血管疾病（如 AMD 等）为主的视网膜疾病全球市场规模接近 200 亿美元，且仍处于增长中。而传 ...